GPEx cell line engineering technology is a flexible cell line development methodology capable of shortening the time to clinic
for recombinant proteins that require production in mammalian cells. Large quantities of recombinant proteins/antibodies can
be produced from pooled cell lines along the path to candidate cell line selection, which in turn shortens timelines and eliminates
the need for separate, large-scale transient transfection experiments. GPEx cell lines producing antibodies express at levels
of 0.7–1.4 g/L in fed-batch bioreactor manufacturing using generic conditions. These levels are on the upper end of production
needed to produce clinical material and will improve with more detailed cell line process development.
Table 1. Clonal Cell Line Production During Bioreactor Manufacturing.
Paul Weiss, Ph.D, M.B.A., is president of the Gala Biotech business unit of Cardinal Health PTS, Gregory Bleck, Ph.D., is director of molecular biology, and Jennifer Franklin is quality control supervisor. Cardinal Health PTS, 8137 Forsythia St., Middleton WI, 1.608.824.9920, fax 1.608.824.9930,
1. Bleck GT. An alternative method for rapid generation of stable, high-expressing mammalian cell lines. Bioprocessing Journal 2005:September/October.
2. Andrake MD, Skalka AM. Retroviral integrase, putting the pieces together. J. Biol. Chem. 1996:271;33;19633-19636.
3. Wu X, Li Y, Crise B, Burgess SM. Transcription start regions in the human genome are favored targets for MLV integration.
4. Mitchell RS, Beitzel BF, Schroder ARW, Shinn P, Chen H, Berry CC, Ecker JR, Bushman FD. Retroviral DNA integration: ASLV,
HIV and MLV show distinct target site preferences. PLOS Biology 2004:2;8;1127-1137.
5. De Palma M, Montini E., Santoni de Sio FR, Benedicenti F, Gentile A, Medico E, Naldini L. Promoter trapping reveals significant
differences in integration site selection between MLV and HIV vectors in primary hematopoietic cells. Blood 2005:105;6; 2307-2315.